Blood and Marrow Transplantation Reviews: Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.